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Vascular Contraction and Preeclampsia
Downregulation of the Angiotensin Receptor 1 by Hemopexin In Vitro
Winston W. Bakker, Rob H. Henning, Willem J. van Son, Maria G. van Pampus, Jan G. Aarnoudse,
Klary E. Niezen-Koning, Theo Borghuis, Rianne M. Jongman, Harry van Goor, Klaas Poelstra,
Gerjan Navis, Marijke M. Faas
Abstract—During normal pregnancy, in contrast to preeclampsia, plasma hemopexin activity is increased together with a
decreased vascular angiotensin II receptor (AT1) expression. We now tested the hypothesis that hemopexin can
downregulate the AT1 receptor in vitro. Analysis of human monocytes or endothelial cells by flow cytometry showed
decreased membrane density of AT1 exclusively after incubation with active hemopexin, whereas in supernatants of
these cell cultures, AT1 molecules could be detected (dot blotting). Also, diminished AT1 was observed in endothelial
cell lysates after contact with hemopexin (Western blotting). Hemopexin also induced extracellular signal–regulated
kinase 1/2 pathway inhibition in cells after stimulation with angiotensin II in vitro, indicating downregulation of AT1
by hemopexin. In addition, functional loss of AT1 occurred after incubation of rat aortic rings with active hemopexin,
as reflected by decreased contraction of the aortic rings on stimulation with angiotensin II. It was further demonstrated
that plasma from normal pregnant women decreased the AT1 receptor expression on monocytes as compared with
plasma from nonpregnant women or preeclamptic women. Finally, it was shown that plasma hemopexin activity
increases during normal gestation from week 10 onward. We concluded that active hemopexin is able to downregulate
the AT1 receptor in human monocytes, endothelial cells, and rat aortic rings. We propose that the physiological role of
enhanced hemopexin activity during healthy pregnancy is to downregulate the vascular AT1 receptor, promoting an
expanded vascular bed. Inhibition of hemopexin activity during preeclampsia may result in an enhanced AT1 receptor
expression and a contracted vascular bed. (Hypertension. 2009;53:959-964.)
Key Words: pregnancy  preeclampsia  hemopexin activity  angiotensin receptor 1
 peripheral vascular resistance
Preeclampsia (PE) is a major complication of pregnancyaffecting 6% of pregnant women in the Western
world.1 The syndrome is clinically characterized by hyper-
tension, proteinuria, and often edema in the second half of
pregnancy. Both severe (early onset) and mild forms of this
disorder are recognized, as well as severe variants with liver
involvement (hemolysis, elevated liver enzymes, and low
platelets syndrome).2 The etiology of PE is unknown,
whereas the pathophysiology is poorly understood. The
general consensus at this moment is that a systemic inflam-
matory response associated with endothelial cell dysfunction
plays a central role in the pathophysiology of PE. Current
thinking focuses on activation of both inflammatory cells and
circulating factors, causing endothelial cell dysfunction. For
instance, a soluble fms-like kinase 1, an antagonist of
vascular endothelial growth factor, may lead to systemic
endothelial alterations, including glomerular endotheliosis.3
An important physiological adaptation of normal preg-
nancy is the increase in cardiac output and blood volume,
together with a decrease in peripheral vascular resistance.4,5
These physiological changes are already apparent very early
in pregnancy and appear to be maximal between weeks 15
and 25 and remain relatively stable until the end of pregnan-
cy.4,5 The hemodynamic changes during pregnancy are prob-
ably caused (at least in part) by changes in the renin-angio-
tensin-aldosterone system. One of those changes includes
decreased vascular responsiveness to angiotensin II (Ang II),
starting approximately at week 10.6,7 This drop in responsive-
ness to Ang II may be attributed to decreased vascular
expression of the Ang II receptor (AT1) receptor during
normal pregnancy.8–11 In PE, however, maternal hemody-
namics are characterized by relative hypovolemia, enhanced
total peripheral resistance, and impaired uteroplacental per-
fusion.6,7 The contracted vascular bed in these patients is
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associated with the persisting vascular responsiveness on Ang
II during the entire gestational period.6,7 Accordingly, an
upregulation of vascular AT1 receptors, as compared with
normal pregnancy, was shown in preeclamptic women.8–11
Plasma hemopexin (Hx), a heme binding glycoprotein, has
been shown recently to also exert protease activity.12–14 Thus,
Hx is able to affect extracellular matrix (ECM) molecules of
renal tissue and endothelial cells in vitro, which can be
inhibited by protease inhibitors or nucleotides like ATP.15
Interestingly, enhanced plasma Hx activity occurs in normal
pregnant women as compared with nonpregnant or pre-
eclamptic women.16 Because this enhanced plasma activity
occurs together with downregulation of the vascular AT1 in
healthy pregnancy,8–11 we proposed that enhanced Hx activ-
ity in healthy pregnant women may be responsible for this
downregulation. Because of inhibition of Hx activity by
enhanced plasma ATP levels observed in PE,16 it seems likely
that AT1 downregulation does not occur, resulting in a
contracted vascular bed in these patients.
In the present article, it is shown that the AT1 expression
can be downregulated by the active isoform of Hx in vitro in
various cell types expressing AT1, including human endothe-
lial cells. Moreover, functional nonresponsiveness on Ang II
in blood vessel fragments can be induced by incubation of
thoracic artery rings of the rat with active Hx; these data
support the notion that the active isoform of Hx may (during
pregnancy) downregulate AT1, resulting in a decrease of
peripheral vascular resistance. The lack of vascular expansion
in PE in vivo may be related to the absence of active Hx in
these patients.
Materials and Methods
Incubation of Peripheral Blood Mononuclear Cells
or Human Endothelial Cells With Hx
Peripheral blood mononuclear cells (PBMCs), isolated from EDTA
blood samples obtained from healthy volunteers using standard
methods, were washed in Hank’s balanced salt solution and resus-
pended in tissue culture medium (RPMI 1640; 1106 cells per mL)
and incubated with either active Hx (200 g/mL) or the same amount
of heat-inactivated Hx (Hxi) or washed in saline under standard
conditions for 2 hours (37°C; 5% CO2; Hxi was prepared by heating
at 80°C for 60 minutes). After the incubation, cells were centrifuged
(2000 rpm) for 10 minutes; supernatants were collected and frozen
(20°C) until measurement of the AT1 level using Western blot
analysis. The cells were resuspended in PBS and analyzed for AT1
receptor expression using flow cytometry (please see the online data
supplement at http://hyper.ahajournals.org). In another set of exper-
iments, cells were incubated with plasma diluted in PBS (1:10)
obtained from patients with PE (n4), healthy pregnant women
matched for gestational age (n5), or age-matched nonpregnant
control women (n5; please see the online data supplement).
Human umbilical venous endothelial cells (HUVECs), passage 3,
were obtained from the University Medical Centre Groningen
Division of Medical Biology and cultured according to standard
methods using 6-well tissue culture plates. Confluent cultures were
incubated with either 200 g/mL of active Hx or the same amount of
Hxi or saline as described for PBMCs, harvested using a rubber cell
scraper (Corning Inc) after 2 hours, and subsequently washed and
prepared for flow cytometry for measurement of AT1 receptor
expression (please see the online data supplement).
Patients
The present study was performed after approval by the medical
ethics committee of the University Medical Center Groningen.
Written informed consent was obtained from all of the patients. PE
patients and healthy pregnant controls were recruited from the
antenatal ward of the University Medical Center Groningen. Blood
samples were taken from PE patients and healthy pregnant control
women, as well as from nonpregnant women. The nonpregnant
women were recruited from hospital staff and students (please see
the online data supplement).
Dot Blot Assays for the AT1 Receptor in
Supernatants From PBMC Cultures
For dot blot analysis of the AT1 receptor in culture supernatants in
PBMCs, BioBlot nitrocellulose membranes (Costar Cambridge Can-
ada) and the BioDot apparatus (BioRad Laboratories) were used. The
AT1 receptor was measured in supernatants of cultures from PBMCs
stimulated with active Hx, Hxi, or saline according to standard
methods (please see the online data supplement).
Western Blotting for the AT1 Receptor in
Endothelial Cell Extracts
Confluent human endothelial cell cultures (cell line ECV340) were
cultured in medium 199 containing 10% fetal calf serum under
standard conditions. After washing with Hanks’ balanced salt solu-
tion, cultures were incubated for 120 minutes with Hx (200 g/mL)
under serum-free conditions and subsequently washed. Control
incubations were done with Hxi. After washing with PBS, cell lysates
were prepared and subjected to 7.5% SDS-PAGE and transferred to a
nitrocellulose membranes (BioRad Laboratories) according to standard
methods (please see the online data supplement).
AT1 Receptor Downregulation by Hx in Smooth
Muscle Cell Lysates as Shown by Inhibition of the
Phosphorylation of Mitogen-Activated Protein
Kinase Extracellular Signal–Regulated Kinase 1/2
This test system is based on phosphorylation of the mitogen-acti-
vated protein kinase extracellular signal–regulated kinase (ERK) 1/2
in cells expressing the AT1 receptor. This phosphorylation occurs on
binding of Ang II to the AT1 receptor. The protocol used was carried
out with vascular smooth muscle cells (VSMCs) of Wistar rats,
which were kindly provided by L.E. Deelman (Department of
Clinical Pharmacology, University Medical Centre Groningen), ac-
cording to standard methods (please see the online data supplement).
Evaluation of Hx Activity in Plasma From
Pregnant Women
For measurement of Hx activity during pregnancy, after signing
informed consent, blood samples (EDTA, Vacutainer) were taken of
6 pregnant women throughout the entire period of pregnancy.
Sampling started at week 5, and samples were taken every 5 weeks
until the end of pregnancy. These women were under standard
control with midwives, and their pregnancy remained normal
throughout the entire gestational period. Exclusion criteria were the
presence of known diseases. Samples were measured for Hx activity
using the standard ECM stripping assay.12–15 This assay is based on
the protease activity of Hx evaluated after incubation of kidney tissue
with plasma samples with or without anti-Hx IgG. Decrease of
expression of glomerular ectoapyrase, reflected by a loss of reaction
product, indicates Hx activity of the sample tested and is calculated
and expressed as arbitrary units of Hx activity.14
Aortic-Ring Contraction Studies
The effect of Hx on stimulation of aorta tissue with Ang II was
studied using standard isotonic contraction experiments with tho-
racic aorta rings of the rat pretreated with NG-monomethyl-L-
arginine (L-NNMA) (104 mol/L for 15 minutes) to inhibit NO
synthase according to standard methods.17 Because the vascular
response to Ang II is mediated through a variety of receptors,
including AT1, Ang II type 2 (AT2), and possibly additional
receptors for cleavage products, without L-NNMA the vascular
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response for Ang II is highly variable because of differences in
receptor types in individual animals. To obtain reproducible and
specific responses, L-NNMA is used in this standard assay.17 Aortic
rings from normal Wistar rats were kept in Krebs solution (at 37°C,
5% CO2, 95% O2), and the cumulative concentration-response
curves for Ang II (1010 to 106 mol/L) were evaluated after
incubation of the tissue with either active Hx (105 mol/L; n5) or
control medium (n5). Vasoconstriction responses were expressed
as a percentage of maximal contraction after stimulation with
phenylephrine (105 mol/L).
Statistics
For evaluation of the experiments in which PBMCs or HUVECs
were incubated with Hx or plasma, statistical analysis was performed
using the Wilcoxon’s signed-rank test, and differences were consid-
ered significant if P0.05. For the experiments in which aortic rings
were incubated with Hx, differences between concentration-response
curves were evaluated by 1-way ANOVA for repeated measurements
followed by the Bonferroni posthoc test (SPSS for Windows Stan-
dard version 8.0, SPSS Inc). Differences were considered significant
at a level of P0.05.
Results
Data obtained after flow cytometry for the detection of the
expression of AT1 receptor on monocytes or HUVECs are
shown in Figure 1. After incubation of PBMCs with active
Hx, the mean percentage of AT1 receptor–positive monocytes
shows a significant decrease as compared with monocytes
incubated with Hxi (Figure 1A and 1B; Because incubation
with saline showed the same results as compared with Hxi
throughout all of the experiments, data with saline incubation
are not shown). In HUVECs, no significant drop in the
percentage of positive cells could be observed (Figure 1C).
However, when the mean channel brightness of the AT1
receptor–positive cells was measured, reflecting mean AT1
receptor density, a significant reduction of AT1 receptor
expression was seen after incubation with active Hx versus
Hxi or saline (Figure 1D). In Figure 2, it is shown that the
expression of the AT2 receptor has increased after stimulation
of cells with active Hx versus Hxi or control medium. With
respect to the effect of active Hx on Ang II–mediated
contraction of aorta rings in vitro, Hx significantly reduced
aortic contraction to cumulative doses of Ang II compared
with incubation medium (Figure 3).
Dot blot analysis of supernatants of PBMC cultures after
incubation with active Hx shows the presence of increased
amounts of AT1 receptor in contrast to control supernatants
(ie, after incubation with Hxi or saline; Figure 4A and 4B). In
addition, Western blotting of cell lysates prepared from
endothelial cell cultures after incubation with Hx showed a
decreased amount of the AT1 receptor as compared with
incubation with heat-inactivated Hx (Figure 5).
Immunostaining for phosphorylated ERK1/2 using West-
ern blots represented activation of this mitogen-activated
protein kinase through stimulation of the AT1 receptor by
Ang II. Also this test system showed downregulation of the
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Figure 1. Flow cytometry data showing the mean (SD) per-
centage of AT1 receptor–positive human monocytes (n23; A)
or HUVECs (n5; C) or the mean channel brightness of the AT1
receptor on monocytes (B) or HUVECs (D). Cells have been
incubated with either control medium (), active Hx (f), or Hxi
(p). It can be seen that exclusively after incubation with active
Hx, the percentage of cells expressing the AT1 receptor is
downregulated in monocytes (A) but not in HUVECs (C). How-
ever, mean channel brightness of the AT1 receptor expression is
significantly decreased in both monocytes and HUVECs after
contact with active Hx (B and D). *P0.05, Wilcoxon (active Hx
vs Hxi).































Figure 2. Flow cytometry data showing mean (SD) percent-
ages of AT2 receptor–positive human monocytes (n5; A) or the
mean channel brightness of the AT2 receptor on monocytes (B).
Cells have been incubated with control medium (), active Hx
(f), or Hxi (p). It can be seen that, exclusively after incubation
with active Hx, the percentage of cells expressing the AT2
receptor and the mean channel brightness is upregulated in
these cells (P0.01, active Hx vs Hxi, A; P0.05, active Hx vs
Hxi, B, Wilcoxon).



























Figure 3. The inhibitory effect of preincubation with active Hx on
cumulative Ang II concentration-response curves in thoracic
aorta rings of the rat. Thoracic rings were preincubated with
vehicle (control; rhombus; n5) or active Hx (105 mol/L,
squares; n5) for 15 minutes before administration of Ang II.
Experiments were conducted in Krebs solution (37°C, 5% CO2,
95% O2) in the presence of L-NNMA (10
4 mol/L). Maximum
contraction for phenylephrine amounted to 285.127.7- and
302.160.0-m transducer displacement in the presence vs the
absence of Hx, respectively; this difference is statistically not
significant. *Significant difference between curves (ANOVA for
repeated measurements, P0.01).
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incubation of VSMCs with Hx, in contrast to Hxi, leads to
decreased staining of the phosphorylated ERK1/2, as re-
flected in Figure 6.
The studies with plasma samples from either subjects with
PE or healthy pregnant women show decreased AT1 receptor
expression in monocytes after incubation with plasma from
pregnant individuals as compared with cells incubated with
plasma from nonpregnant women (Figure 7). The expression
of the AT1 receptor in monocytes after contact with PE
plasma also showed a loss of AT1 receptor expression,
although to a lesser extent as compared with plasma from
normal pregnant women. Figure 8 shows mean activities of
plasma Hx in samples from healthy pregnant women during
the entire period of pregnancy. It appeared that Hx activity
gradually increased during pregnancy, starting around week 10.
Discussion
The aim of the present study was to test our hypothesis that
Hx may be able to downregulate the AT1 receptor in vitro
from cells expressing this receptor. Because both PBMCs and
endothelial cells showed a loss of expression of the AT1
receptor after contact with active Hx (Figure 1), it is likely
that active Hx was indeed able to downregulate this receptor.
The data in Figure 4A and 4B clearly show that shedding of
the AT1 receptor seems the most likely mechanism. It is clear
from Figure 1C and 1D that the outcome of the Hx effect
depended on the method of expression of the data. Thus,
whereas the mean decrease of the percentage of AT1–positive
monocytes reflected the loss of all of the AT1 receptors per
cell leading to a decrease of a number of positive cells, the
mean decrease of intensity (mean channel brightness) re-
flected the loss of only a part of the receptors per cell after
contact with active Hx. It can be deduced from these data that
the downregulation of the AT1 receptors in HUVECs by
1 2 3 Hxa(1) Hxa(2)Hxi(1) Hxi(2)



































Figure 4. A, Immunostaining of dots of supernatants from
PBMC cultures before and after stimulation with 2 different
batches of active Hx (Hxa1 and Hxa2) or Hxi, as indicated. Top,
Control dots without the first antibody (anti–AT1 receptor); some
faint background staining can be seen. Bottom, In duplo: nega-
tive dots (lanes 1 and 2) or slight background staining (lane 3)
and positive staining of spots containing supernatants from cul-
tures incubated with either active Hx or Hxi. Lanes 1, 2, and 3
contain Tris-buffered saline, tissue culture medium, and super-
natant from unstimulated cell cultures, respectively. It can be
seen that the most prominent stained dots are derived from
supernatants from cultures incubated with active Hx (Hxa1 and
Hxa2) vs control culture supernatants derived from cultures
stimulated with Hxi (Hxi1 and Hxi2). B, Mean staining intensity
(SD) of dots after staining with anti–AT1 IgG after culture with
supernatant from unstimulated cells (), active Hx (f), or Hxi
(p). It is shown that contact with active Hx results in increased
amounts of AT1 receptor (or receptor fragments) in the medium
of the cells vs control cells and cells incubated with Hxi.
*P0.01, Hxa vs control and Hxi (Wilcoxon).
Figure 5. Western blots of endothelial cell lysates after immuno-
staining for AT1 receptors. Lane 3 (control) shows a band of
42 kDa reflecting AT1 receptor molecules. Cell lysates from
cell cultures preincubated with active hemopexin (2 different
batches, Hx1 and Hx2) show decreased staining of AT1 recep-
tors (lanes 1 and 2) in contrast to lysates from cells incubated
with Hxi (lane 3). Bottom, Loading controls of the same cell
lysate samples from cells incubated with either Hx or Hxi,
stained for -actine.
Figure 6. Western blots of VSMC lysates after immunostaining
for phosphorylated ERK1/2. It can be seen that lysates from
VSMCs derived from Ang II–stimulated cell cultures with previ-
ous contact with Hxi show 2 adjacent bands of 43 kDa,
reflecting phosphorylated ERK1 and ERK2 (lane 1). Decreased
staining of phosphorylated ERK1/2 can be seen after preincuba-
tion of the stimulated VSMCs with active Hx (lane 2). Stimulation
of the cell cultures was done with 1.0 nmol/L angiotensin II.
Bottom, Loading controls of the same cell lysate samples from
cells incubated with either Hx or Hxi, stained for -actine.























Figure 7. Flow cytometry data showing mean percentage
( SD) of monocytes expressing the AT1 receptor after incuba-
tion of the cells with plasma from healthy nonpregnant control
women (; n5), normal pregnant women (f; n5), and PE
patients (p; n4). It can be seen that cells after contact with
plasma from pregnant women (containing active Hx) show
decreased expression of the AT1 receptor. Although consider-
able downregulation of the AT1 receptor is also seen after con-
tact of the cells with plasma from PE patients (containing Hxi),
this occurs to a significantly lesser extent vs plasma from nor-
mal pregnant women. *P0.01, pregnant plasma vs nonpreg-
nant plasma (Wilcoxon). **P0.01, PE plasma vs pregnant
plasma (Wilcoxon). #P0.01, PE plasma vs nonpregnant plasma
(Wilcoxon).
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active Hx was less prominent as compared with this effect in
monocytes. The reason for this remains to be investigated. It is
conceivable that the nature of AT1 receptor expression in both
cell types is not identical, which may explain this discrepancy.
Be this as it may, it is clear that also in endothelial cells a
significant reduction of AT1 expression occurred after contact
with active Hx. As concomitant with downregulation of AT1,
upregulation of the AT2 receptor occurred after stimulation
with Hx (Figure 2), and it is clear that exclusively shedding of
the AT1 receptor was induced by active Hx. Both Ang II
receptor subtypes AT1 and AT2 were able to bind Ang II.
However, downregulation of the AT1 receptor often leads to
upregulation of the AT2 receptor.18 The mechanism of AT1/
AT2 interaction after binding of Ang II is poorly under-
stood.19 Because Ang II receptor trafficking between cell
membrane and cytosol occurs,20 it is conceivable that non-
genomic mechanisms are involved in upregulation of AT2
receptors concomitantly with enzymatic removal of AT1 recep-
tors after contact with active Hx. Be this as it may, the present
data show an antagonistic effect regarding AT1 versus AT2
expression, which is in line with data from other authors.21
Downregulation of the AT1 receptor seems also reflected
by inhibition of the contraction of aorta rings by active Hx
after stimulation with Ang II (Figure 3). However, although a
significant decrease of aorta ring contraction during contact
with active Hx is seen in these experiments, it cannot be
concluded from these data whether this is because of either
enzymatic shedding or blocking of this receptor by active Hx.
In view of the present data with isolated cells, however
(Figures 1 and 4), it is suggested that enzymatic cleavage of
the AT1 receptors by active Hx may be considered as a
mechanism by which this nonresponsiveness on Ang II
stimulation is induced. Because the contraction induced by
the ˜-adrenergic receptor agonist phenylephrine was not
affected by Hx, it seems unlikely that the effect of Hx was
caused by a general influence on signal transduction pathways or
calcium handling. Therefore, we feel that downregulation of this
vascular response on Ang II by active Hx may be specific.
If active Hx is indeed able to promote shedding of the AT1
receptor from cell surfaces, it should be expected that this
molecule is detectable in supernatants of cell cultures treated
with active Hx. This indeed appears to be the case. The
observed increase of the AT1 receptor in supernatants of
PBMC cultures after incubation with active Hx, as shown in
Figure 4, therefore supports the assumption that active Hx
removed the AT1 receptor from the cells studied. This notion
is enhanced by the Western blot data of Figure 5, showing
reduced AT1 staining in endothelial cell lysates after incuba-
tion of endothelial cells with active Hx. Taking advantage of
the immediate phosphorylation of the mitogen-activated pro-
tein kinase ERK1/2 after stimulation of the AT1 receptor by
Ang II, also using this test system, it is clear that downregu-
lation of the AT1 receptor occurred after contact of the cells
with active Hx. Because active Hx contains protease activity,
able to enzymatically affect various cell membrane constitu-
ents and ECM,12–14 it is highly likely that this was mediated
by the protease activity of active Hx. However, the precise
mechanism of this putative shedding of AT1 receptors from
cell surfaces remains to be established. Because the blotting
technique is based on immunologic detection of AT1 receptor
antigens using a polyclonal antibody, it is possible that both
the AT1 receptor and fragments of this molecule are recog-
nized. If active Hx also induces shedding of AT1 in vivo, the
question as to the function of soluble AT1 emerges. Up to
now, a potential function for shedded AT1 receptors or
receptor fragments in vivo is unknown. We considered the
possibility that active Hx does not enzymatically hydrolyze
AT1 directly but acts through stimulation of other
membrane-bound enzymes, eg, adamalysine 17. These
so-called sheddases are able to promote shedding of various
membrane-associated molecules, eg tumor necrosis factor .22
Preliminary data, however, showed that inhibition of adama-
lysine 17, with its inhibitor tumor necrosis factor  protease
inhibitor 1, did not affect the downregulation of the AT1
receptor after incubation of the cells with active Hx, suggest-
ing that Hx is able to enzymatically remove the AT1 receptor
directly from cell membranes. To exclude the involvement of
other sheddases, studies are in progress to test more sheddase
inhibitors, including metalloproteinase inhibitors. With respect
to the AT2 receptor expression, it is clear that AT2 is signifi-
cantly upregulated by active Hx, suggesting that the balance
between AT1 and AT2 expression may be under the control of
active Hx (Figure 2). This is in line with the observation that the
AT2 receptor may also be involved in vascular responses in
normal and complicated pregnancies.18 However, as stated
above, the molecular mechanism underlying AT1/ AT2 interac-
tions is unclear.
Similar downregulation of the AT1 receptor occurs when
PBMCs are incubated with plasma from healthy pregnant
individuals (Figure 7). Because these plasma samples contain
active Hx,16 we ascribe this effect to the presence of Hx in
these samples. Incubation of cells with plasma samples from
subjects with PE unexpectedly also showed significant down-
regulation of AT1 receptor as compared with plasma from
nonpregnant and pregnant control individuals. This may
reflect the presence of Hx activity in these plasma samples.
However, using the ECM stripping assay, we demonstrated
previously that PE plasma does not show Hx activity. This
inhibition is because of the relatively high titers of ATP,






























Figure 8. Mean Hx activity (SD) of plasma from nonpregnant
(t0) and normal pregnant women assayed at various time
points of pregnancy (n8). Hx activity, expressed as arbitrary
units, was measured using the standard ECM stripping assay. It
can be seen that Hx activity gradually increases during preg-
nancy, starting approximately on week 10 and plateauing after
week 15. Mean Hx activity in plasma samples from weeks 15 to
40 is significantly increased vs mean Hx activity in samples from
nonpregnant women (timepoint 0). *P0.01, Wilcoxon.
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which inhibit Hx activity.16 The apparent discrepancy ob-
tained in the current experiments, however, can be explained
by assuming that contact of PE plasma with living cells
expressing ectophosphatases on their surface promotes hy-
drolysis of ATP, leading to reactivation of Hx in the PE
plasma samples tested. Indeed, experimental evidence is
accumulating that contact of PE plasma with living PBMCs
may partially activate Hxi in this plasma (results not shown).
In other words, it is likely that this reactivation of Hxi to
active Hx has occurred during the incubation steps necessary
for the flow cytometry assays. In spite of this disturbing
reactivation of Hxi in PE plasma samples, it is clear that
plasma from pregnant women contains more Hx activity as
compared with that of subjects with PE.
Perspectives
Previously we described enhanced Hx activity in plasma from
healthy pregnant women, in contrast to women with PE,
occurring in the third trimester of pregnancy.16 From Figure
8, it can be seen that the rise of Hx activity starts approxi-
mately on week 10. Also around the gestational age of week
10 in healthy pregnant individuals, the nonresponsiveness on
Ang II is observed.5,6 This persists throughout the entire
period of pregnancy, leading to a relatively expanded vascu-
lar bed, beneficial for proper placental perfusion, as com-
pared with age-matched nonpregnant women. Because the
nonresponsiveness of vessels on Ang II may be attributable to
vascular loss of AT1,7 it is tempting to speculate that the
function of enhanced Hx activity in normal pregnancy is to
promote shedding of the vascular AT1 receptor, leading to
vascular expansion. Interestingly, in healthy pregnant rats,
enhanced plasma Hx activity is also associated with de-
creased AT1 receptor expression (MM Faas et al, unpublished
data, 2009). The hypothesis is in line with the situation in PE
lacking Hx activity because of enhanced titers of plasma
ATP.16 In PE, the AT1 receptor expression is relatively
increased8–11 and vascular responsiveness on Ang II is
persisting, leading to a contracted vascular bed and resulting
in detrimental consequences for placental perfusion. We feel
that potential treatment strategies for PE should focus on
reactivation of Hx activity, ie, by treatment of PE patients
with alkaline phosphatase, or other ATP hydrolyzing princi-
ples. This suggestion is corroborated in vivo, in which
smoking, per se, is associated with increased plasma alkaline
phosphatase activity and decreased incidence of PE.23
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Expanded Materials and Methods: 
Patients 
The present study was performed after approval by the medical ethics committee of 
the University Medical Center Groningen. Written informed consent was obtained 
from all patients. PE patients and healthy pregnant controls were recruited from the 
antenatal ward of the University Medical Center Groningen. Blood samples were 
taken from PE patients and healthy pregnant control women as well as from non-
pregnant women. They were recruited from hospital staff and students. Exclusion 
criteria for all groups were pre-existent hypertension, diabetes mellitus, vasculitis, 
renal disease, autoimmune disease, malignancy or women who had recent trauma or 
surgery. 
PE was defined according to the standards of the International Society for the Study 
of Hypertension in Pregnancy (ISSHP): diastolic blood pressure of 90 mmHg or more 
on two or more consecutive occasions more than 4 hrs apart and proteinuria of more 
than 300 mg/24 hours. Maternal blood samples of both pregnant and preeclamptic 
women were collected during routine blood sampling during pregnancy/preeclampsia. 
Blood samples were drawn from the antecubital vein into 10-mL tubes containing 
EDTA (Venoject, Terumo Europe NV, Leuven, Belgium). Samples were immediately 
stored at 4 °C and centrifuged within 1 hour. They were centrifuged at 130 g for 10 
minutes at 4 °C; subsequently the plasma was centrifuged at 700 g for 10 minutes. 
The platelet poor plasma samples were frozen at -80 °C. 
 
Flow Cytometry of PBMC and HUVEC: 
To evaluate the expression of AT-1 receptor upon blood cells or HUVEC, PBMC 
from healthy female donors were washed (x2) in PBS supplemented with 1% bovine 
serum albumin (PBS/BSA) and subsequently incubated with monoclonal anti AT-1 
IgG (clone TONI, Abcam) or anti AT-2 IgG (clone 364805 R&D ;UK), or non 
immune mouse IgG, at 0 ºC. After 30 min. cells were washed (x2) in PBS/BSA buffer 
and incubated with goat-anti-mouse IgG FITC (DAKO) for 30 min at 0º C. For 
control staining, cells were incubated with the second antibody only (i.e. goat-anti 
mouse-IgG FITC). After another wash (x2) with BSA/PBS cells were fixed with 
paraformaldehyde (2%). The fluorescence was measured by flow cytometry using a 
FACS device (Calibur Beckton Dickinson, USA)). PBMC suspensions containing 
1x105 cells were assayed. The data were processed using a standard software program 
(Winlist 6.0). For PBMC analysis, monocytes were gated in the forward-
sidescatterplot and this gate was copied to a histogram. For HUVEC a gate was set on 
the HUVEC population and this gate was also copied to a histogram. In the histogram, 
control incubations (second antibody only) were gated in such way that 99% of the 
cells were negative for FITC. This gate was then copied to the samples which were 
incubated with AT-1 receptor antibody. Percentage positive cells was used as a 
standard for AT-1 expression; mean channel brightness of the positive cells, reflecting 
AT-1 receptor density, was also calculated. 
 
Dot blot assays for AT-1 receptor in supernatants from PBMC cultures. 
For dot blot analysis of the AT-1 receptor in culture-supernatants in PBMC, BioBlot-
nitrocellulose membranes (Costar Cambridge Canada) and BioDot apparatus (BioRad 
Labs) were used.  AT-1 receptor was measured in supernatants of cultures from 
PBMC stimulated with active Hx, Hxi or saline according to standard methods. 
Supernatants were applied on the membrane (100 µl) and incubated for 60 minutes at  
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room temperature. The sheets were washed (x4) with Tris buffered saline (TBS). The 
sheets were removed from the dot blot device and further incubated for 60 min with 
5% skim milk (ELK;Campina, The Netherlands) and subsequently washed with TBS 
supplemented with Tween-20 (0,05%) (TBS-Tween), followed by incubation 
overnight with the rabbit-anti-human AT-1 receptor IgG (N10; Santa Cruz, USA) and 
washed with TBS containing 2.0% ELK. After washing (x2) in TBS-Tween, sheets 
were incubated with goat-anti-rabbit IgG conjugated with alkaline phosphatase 
(1:2000) for 60 minutes. Stain development was done with nitro blue tetrazolium 
(NBT) and 5-Bromo-4-chloro-3-indolyl phosphate disodium salt (Sigma-Aldrich, 
Germany). After drying of the sheets, blots were scanned and the staining intensity 
was quantified using “Quality One” software program (Biorad). 
 
Western blotting for AT-1 receptor in endothelial cell extracts. 
Confluent human endothelial cell cultures (cell line ECV340) were cultured in 
Medium 199 containing 10% fetal calf serum under standard conditions. After 
washing with Hanks' balanced salt solution (HBSS), cultures were incubated for 120 
minutes with hemopexin (200 μg/ml) under serum free conditions and subsequently 
washed. Control incubations were done Hxi. After washing with PBS, cell lysates 
were prepared and subjected to 7.5% SDS polyacrylamide gel electrophoresis (PAGE) 
and transferred to a nitrocellulose membranes (Biorad) according to standard 
methods. Cell lysates were prepared by using 150 μl lysis buffer per 6 x 105 cells 
(10mM Tris, pH 7.5; 1 mM  EDTA, 4% SDS, 20% glycerol, 10% β-mercapto-
ethanol,  25mM NaF, containing freshly prepared 100μM Na3VO4, 1mM 
phenylmethane sulfonylfluoride ,4 μg/ml aprotinin and bromophenyl blue). The 
lysates were heated in a boiling water bath for 5 minutes and subsequently sonicated 
for 5 seconds followed by centrifugation for 10 minutes at 10.000 x g. Samples were 
subjected to 7.5% SDS polyacrylamide gel electrophoresis (PAGE) and transferred to 
a nitrocellulose membranes (Biorad) according to standard methods. The membranes 
were immunostained with mouse monoclonal antibody to the AT-1 receptor (Abcam, 
ab9391), followed by anti-mouse IgG conjugated with horseradish peroxidase(HRP) 
according to standard methods. The immunostaining was visualised by enhanced 
chemiluminescense (SuperSignal West Pico Chemiluminescent Substrate from 
Thermo Scientific). 
Loading controls were done using rabbit polyclonal anti β-actine IgG (Abcam 
(ab8227)). Thus, befor restaining, the blots were incubated with stripping buffer 
(0.1M glycine containing 1%SDS, pH 2.0) for 30 minutes. The blots were 
subsequently washed (x3) with Tris buffered saline (pH7.4) and incubated with anti β-
actine IgG  (1:10.000) for 60 minutes. The staining was visualized as described for 
anti AT-1 IgG. 
 
 
AT-1 receptor downregulation by hemopexin in smooth muscle cell lysates as 
shown by inhibition of the phosphorylation of  MAP kinase ERK1/2.  
This test system is based upon phosphorylation of the MAP kinase ERK1/2 in cells 
expressing the AT-1 receptor. This phosphorylation occurs upon binding of 
angiotensin II (Ang II) to the AT-1 receptor. The protocol used was carried out with 
vascular smooth muscle cells of Wistar rats (VSMC), which were kindly provided by 
Dr L.E. Deelman (Department of Clinical Pharmacology, UMCG, Groningen), 
according to standard methods. Confluent cells (passage 3-6) were cultured in  
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Dulbecco’s Modified Eagle’s Medium containing 10% fetal calf serum under standard 
conditions. Before use, cells were washed with HBSS and subsequently incubated 
with 200 μg/ml Hx or Hxi for 120 minutes under serum free conditions. After 
incubation  cells were washed and incubated with Ang II (1.0 nM/ml)) for 5 minutes 
followed by the preparation of cell lysates as described above. The lysates were 
subjected to 10% SDS PAGE  followed by blotting to nitrocellulose membranes 
according to standard methods. Immunostaining was done with a mouse monoclonal 
antibody against  phosphorylated ERK1/2 (Santa Cruz; SC 7383) and by rabbit anti 
mouse IgG conjugated to HRP (DAKO,PO260) as a second step. The staining was 
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